Exelixis, Inc. 10-Q Summary: Period Ended June 30, 2005
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2005. Exelixis, Inc. is a biotechnology company focused on developing pharmaceutical products for cancer, metabolic disorders, and cardiovascular disease. The company operates primarily through internal research and development and strategic collaborations with major pharmaceutical partners. As of July 29, 2005, there were 76,565,908 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2005 | Six Months Ended June 30, 2005 |
|---|---|---|
| Total Revenues | $34,310 | $47,184 |
| Net Loss | $(9,696) | $(37,107) |
| Net Loss Per Share (Basic/Diluted) | $(0.13) | $(0.49) |
| Cash and Cash Equivalents | $104,821 | $104,821 (Balance Sheet) |
| Total Current Assets | $197,911 | $197,911 (Balance Sheet) |
| Total Current Liabilities | $91,893 | $91,893 (Balance Sheet) |
| Working Capital | $106,018 | $106,018 (Calculated) |
| Long-Term Debt (Notes & Convertible Loans) | $107,380 | $107,380 (Balance Sheet) |
Note: The company reported a net loss for the period. Operating cash flow used $7.5 million for the six months ended June 30, 2005, a significant improvement from the $63.2 million used in the prior year period.
Material Changes vs. Prior Period
- Revenue Surge: Total revenues increased 173% for the three months and 93% for the six months compared to the prior year. This was driven primarily by the termination of the Genoptera collaboration, which resulted in the recognition of $21.1 million in revenue (including a $10.9 million early termination fee and accelerated deferred revenue).
- Collaboration Milestones: The company recognized $5.3 million in milestone revenue in the quarter, largely due to a $30.0 million milestone from GlaxoSmithKline (GSK) for filing INDs for three compounds, and a $5.0 million milestone for progress on other candidates.
- Expense Management: Research and development (R&D) expenses increased slightly (6% for the quarter) due to increased clinical trial activities and royalties related to a new Genentech collaboration, partially offset by a decrease in lab supplies following the termination of combinatorial chemistry collaborations.
- Debt Structure: The company entered into a financing arrangement with Symphony Evolution, Inc. (SEI) in June 2005, receiving $40.0 million to fund clinical development of three compounds (XL784, XL647, XL999). This is reflected in the balance sheet as investments held by SEI and noncontrolling interest.
Guidance, Outlook, and Risks
Outlook and Liquidity: Management anticipates that current cash, short-term investments, and expected collaborator funding will sustain operations for at least the next 12 months. The company expects to incur substantial losses for the foreseeable future as it advances its pipeline.
Key Developments:
- Symphony Evolution, Inc. (SEI): Exelixis licensed three product candidates to SEI in exchange for up to $80 million in funding. Exelixis retains an option to reacquire these programs.
- Genentech Collaboration: A new agreement was signed in May 2005 for the development of Notch pathway therapeutics, with $16.0 million in total funding.
- Helsinn Healthcare: Exelixis licensed XL119 (becatecarin) to Helsinn for worldwide commercialization (excluding North America for specific indications), receiving a $4.0 million upfront payment.
Risks and Contingencies:
- Financing Needs: The company must raise additional capital to fund operations and clinical trials. Failure to do so could force a curtailment of operations.
- Debt Covenants: The company must maintain working capital of at least $25.0 million and cash/investments of at least $50.0 million to comply with GSK loan covenants. As of June 30, 2005, these were met ($106.0M and $202.3M respectively).
- Convertible Note: A $30.0 million convertible promissory note to Protein Design Labs, Inc. matures in May 2006. If not converted, it must be repaid in cash.
- Regulatory and Clinical Risk: Clinical trials are uncertain; failure to demonstrate safety or efficacy could prevent regulatory approval and commercialization.
Investor Verification Checklist
- Repayment of Convertible Note: Verify the company's ability to repay or refinance the $30.0 million note due in May 2006.
- SEI Option Exercise: Monitor the clinical progress of XL784, XL647, and XL999 to determine if and when Exelixis will exercise its option to reacquire these assets from Symphony Evolution, Inc.
- XL119 Supply Chain: Confirm the ability to supply clinical trial materials to Helsinn by the April 30, 2006 deadline to avoid reduced royalties or license termination.
- Cash Burn Rate: Assess the sustainability of the current cash position given the high R&D spend and lack of product sales revenue.
- Stock-Based Compensation: Note that the company currently uses the intrinsic value method (APB 25) for stock compensation; adoption of SFAS 123R in 2006 will materially increase reported expenses.